{"id":"amikacin-injection","safety":{"commonSideEffects":[{"rate":"8-26","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"3-14","effect":"Ototoxicity (hearing loss, tinnitus, vertigo)"},{"rate":null,"effect":"Neuromuscular blockade"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4208954","moleculeType":"Small molecule","molecularWeight":"781.77"},"_dailymed":{"setId":"b834ed2b-d0c5-6db3-e053-2995a90aa963","title":"AMIKACIN SULFATE INJECTION, 500 MG/2ML INJECTION [SAFREL PHARMACEUTICALS, LLC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amikacin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting accurate mRNA translation and causing misreading of the genetic code. This results in production of non-functional proteins and ultimately bactericidal activity against aerobic gram-negative bacteria and some gram-positive organisms. It is particularly effective against resistant gram-negative pathogens including Pseudomonas aeruginosa and Acinetobacter species.","oneSentence":"Amikacin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:05.844Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-negative bacterial infections"},{"name":"Pseudomonas aeruginosa infections"},{"name":"Hospital-acquired infections caused by resistant gram-negative organisms"},{"name":"Mycobacterial infections (including atypical mycobacteria)"}]},"trialDetails":[{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT06097767","phase":"EARLY_PHASE1","title":"the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2023-10-19","conditions":"Pharmacological Action of Drug","enrollment":50},{"nctId":"NCT04035369","phase":"NA","title":"Endophthalmitis Post Intravitreal Injections","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-03-01","conditions":"Endophthalmitis","enrollment":310},{"nctId":"NCT03449459","phase":"EARLY_PHASE1","title":"Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-12-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":144},{"nctId":"NCT04867135","phase":"","title":"Population Pharmacokinetics of Amikacin in Neonates","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2019-12-01","conditions":"Neonatal Sepsis, Late-Onset","enrollment":138},{"nctId":"NCT05213507","phase":"PHASE3","title":"Inhaled Amikacin in Preventing AECOPD","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03","conditions":"COPD, COPD Exacerbation","enrollment":136},{"nctId":"NCT04249531","phase":"PHASE1","title":"Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2020-06-01","conditions":"Tuberculosis","enrollment":8},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT03169114","phase":"NA","title":"Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation","status":"TERMINATED","sponsor":"Raja Isteri Pengiran Anak Saleha Hospital","startDate":"2017-11-01","conditions":"Appendicitis, Surgery","enrollment":81},{"nctId":"NCT02509091","phase":"PHASE4","title":"Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2014-12","conditions":"Bronchiectasis","enrollment":100},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT00362245","phase":"PHASE4","title":"Amikacin Penetration Into the Cerebrospinal Fluid","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2006-09","conditions":"Gram Negative Meningitis, Post Traumatic Bacterial Meningitis","enrollment":""},{"nctId":"NCT00360607","phase":"PHASE4","title":"A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Infection","enrollment":307}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE TONSILLITIS"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CONSTIPATION"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DENTAL CARIES"},{"count":1,"reaction":"DERMATITIS ALLERGIC"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DISEASE RECURRENCE"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG INTERACTION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amikacin","Amikin"],"phase":"marketed","status":"active","brandName":"Amikacin Injection","genericName":"Amikacin Injection","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amikacin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections, Pseudomonas aeruginosa infections, Hospital-acquired infections caused by resistant gram-negative organisms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}